Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF

Rationale: The IPF treatments pirfenidone and nintedanib have overlapping adverse effect profiles with gastrointestinal disorders among the most frequent reasons for drug discontinuation. Further, intraindividual response to pirfenidone treatment varies. It is unknown whether nintedanib can be tolerated and efficacious in patients displaying intolerability or inefficacy of pirfenidone treatment. Objectives: To assess tolerability and efficacy of nintedanib in patients discontinuing pirfenidone due to adverse events. Methods: Retrospective analysis of all patients from the Comprehensive Pneumology Center, Univers…